Business
Vera’s Kidney Drug Nearly Halted Disease Progression in a Two-Year Trial
In its final Phase 3 analysis, Trutakna (atacicept) essentially stabilized kidney function and cut disease-progression events by 76% in IgA nephropathy — strong data as Vera pushes for full FDA approval.